CVAC

CureVac NV

Add to Watchlist

Advanced Chart

5.425

-0.005(-0.092%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.435

Open

5.430

VWAP

5.43

Vol

330.67K

Mkt Cap

1.22B

Low

5.410

Amount

1.79M

EV/EBITDA(TTM)

3.16

Total Shares

224.31M

798.65M

EV/OCF(TTM)

3.52

P/S(TTM)

2.04

CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

0.00

-100%

0.000

-100%

32.56M

+124.57%

-0.070

-50%

34.59M

-93%

-0.150

-110%

Estimates Revision

The market is revising Downward the revenue expectations for CureVac N.V. (CVAC) for FY2025, with the revenue forecasts being adjusted by -8.64% over the past three months. During the same period, the stock price has changed by 0.09%.

Revenue Estimates for FY2025

Revise Downward

-8.64%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+34.53%

In Past 3 Month

Stock Price

Go Up

+0.09%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast CVAC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVAC is 5.50 USD with a low forecast of 5.50 USD and a high forecast of 5.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 5.425

Low

5.50

Averages

5.50

High

5.50

Current: 5.425

Low

5.50

Averages

5.50

High

5.50

UBS

Buy

Neutral

downgrade

$12

2025-06-26

Reason

UBS

Price Target

$12

2025-06-26

downgrade

Buy

Neutral

Reason

UBS downgraded CureVac (CVAC) to Neutral from Buy with a price target of $5.50, down from $12. BioNTech (BNTX) announced the acquisition of CureVac for $5.46 per share, or a total equity value of $1.25B, the analyst tells investors in a research note.

Jefferies

Roger Song

Buy

Hold

downgrade

$7 -> $5

2025-06-12

Reason

Jefferies

Roger Song

Price Target

$7 -> $5

2025-06-12

downgrade

Buy

Hold

Reason

Jefferies analyst Roger Song downgraded CureVac (CVAC) to Hold from Buy with a price target of $5, down from $7, after the company agreed to be acquired by BioNTech (BNTX). Under the terms of the agreement, each CureVac share will be exchanged for $5.46 in BioNTech shares, resulting in an implied aggregate equity value for CureVac of $1.25B.

BofA

Underperform

downgrade

2025-05-21

Reason

BofA

Price Target

2025-05-21

downgrade

Underperform

Reason

BofA lowered the firm's price target on CureVac to $2 from $2.50 and keeps an Underperform rating on the shares. Q1 results highlighted the progression of the pipeline in early-stage clinical studies, but the firm sees work to be done to prove the value of the pipeline and awaits clarity on the patent dispute situation, the analyst tells investors.

JMP Securities

Roy Buchanan

Buy

Reiterates

$16

2025-02-14

Reason

JMP Securities

Roy Buchanan

Price Target

$16

2025-02-14

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for CureVac NV (CVAC.O) is -8.13, compared to its 5-year average forward P/E of -8.34. For a more detailed relative valuation and DCF analysis to assess CureVac NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.34

Current PE

-8.13

Overvalued PE

7.06

Undervalued PE

-23.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.64

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.86

Undervalued EV/EBITDA

-23.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

30.55

Current PS

0.00

Overvalued PS

73.68

Undervalued PS

-12.57